Search clinical trials for: Viral Fusion Protein Inhibitors

Total 12879 results

Trimeris
Hoffmann-La Roche

Completed

Study of Enfuvirtide in HIV-Positive Subjects

HIV Infections | AIDS

United States
Hoffmann-La Roche

Completed

A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection

HIV Infections

Thailand
Hoffmann-La Roche

Completed

A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

Bulgaria
Hoffmann-La Roche
Trimeris

Completed

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche
Trimeris

Completed

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

HIV Infections

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

HIV

United States
National Institute of Allergy and Infectious Diseases...

Completed

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

HIV Infections

United States
Institute for Interdisciplinary Infectiology
Hoffmann-La Roche

Unknown

Cohort Study for Patients Using Fuzeon (Enfuvirtide)

HIV Infections | Antiretroviral Treatment

Germany
Hoffmann-La Roche

Terminated

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

HIV Infection

United States
Hoffmann-La Roche
Trimeris

Completed

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

HIV Infections

United States, Canada, Puerto Rico
Hoffmann-La Roche

Completed

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche
Trimeris

Completed

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

HIV Infections

United States, Australia
Hoffmann-La Roche

Completed

INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

HIV Infections

France
Hoffmann-La Roche

Withdrawn

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

HIV Infections

Australia
National Institute of Allergy and Infectious Diseases...

Unknown

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

HIV Infections

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience (INTENSE)

HIV Infections

France, Germany, Spain, Italy, United States, Switzerland, Netherlands, Mexico, Canada, Israel
Hoffmann-La Roche
Trimeris

Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (AMICI)

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche

Completed

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

France
ViiV Healthcare

Available

Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)

HIV Infections
Hoffmann-La Roche
Trimeris

Completed

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

HIV Infections

United States, Canada
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

HIV Infections

United States, Puerto Rico
Trimeris

Completed

A Study of T-20 in HIV-Positive Adults

HIV Infections

United States
Hoffmann-La Roche
Trimeris

Completed

T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

HIV Infections

Switzerland, Spain, United Kingdom, Germany, Belgium, Australia, Sweden, Italy, Netherlands
CytoDyn, Inc.
Amarex Clinical Research

Active, not recruiting

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

United States
National Institute of Allergy and Infectious Diseases...

Completed

Adding New Drugs for HIV Infected Patients Failing Current Therapy

HIV Infections

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
Hospital Israelita Albert Einstein
CytoDyn, Inc.

Suspended

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

COVID-19 Pneumonia

Brazil
Canadian Immunodeficiency Research Collaborative
Hoffmann-La Roche

Completed

Fuzeon Viral Decay Pilot Study

HIV-1

Canada
GlaxoSmithKline

Terminated

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

HIV Infection

United States, Germany, Belgium, Canada, Denmark
Hoffmann-La Roche
Trimeris

Completed

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

HIV Infections

United States
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

United States, Belgium
PENTA Foundation
ViiV Healthcare; Hospital Universitario 12 de Octubre; Cromsource; PHPT Foundation

Recruiting

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

HIV Infections With Multi Drug Resistant Virus

United States, South Africa, Mexico, Spain
Hospital Israelita Albert Einstein
CytoDyn, Inc.

Suspended

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

COVID-19 Pneumonia

Brazil
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Drexel University
National Institute of Allergy and Infectious Diseases (NIAID)

Withdrawn

PRO 140 for Human Immunodeficiency Virus Infection

HIV

United States
GlaxoSmithKline

Terminated

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

HIV Infection

Germany
National Institute of Allergy and Infectious Diseases...

Completed

GW873140 to Treat HIV-1 Infected Adults

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Infection, Human Immunodeficiency Virus

United States
Tel-Aviv Sourasky Medical Center
Hadassah Medical Organization; Soroka University Medical Center

Recruiting

Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment

Post Stroke Cognitive Impairment

Israel
CytoDyn, Inc.

No longer available

A Compassionate Use Study of Leronlimab in Breast Cancer

Metastatic Triple-Negative Breast Carcinoma
CytoDyn, Inc.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019

United States
Imperial College London
Pfizer

Completed

The Maraviroc Central Nervous System (CNS) Study

HIV Infections

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Infection, Human Immunodeficiency Virus

United Kingdom
Rockefeller University
Pfizer; Aaron Diamond AIDS Research Center

Completed

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

HIV Infections

United States
Kirby Institute
Pfizer; ViiV Healthcare

Completed

Maraviroc Switch Collaborative Study (MARCH)

HIV

Spain, Australia, Ireland, Mexico, Germany, Argentina, Canada, Chile, France, Japan, Poland, Thailand, United Kingdom
Rhode Island Hospital

Completed

Maraviroc in Patients With Moderate and Severe COVID-19

COVID

United States
ViiV Healthcare

Active, not recruiting

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

HIV Infections

United States, Spain, France, Australia, Germany, Belgium, Canada, Argentina, Brazil, Italy, Romania, Mexico, Taiwan, Netherlands, South Africa, Russian Federation, Greece, Portugal, United Kingdom, Poland, Peru, Chile, Colombia, Ireland and more
CytoDyn, Inc.

Withdrawn

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

HIV

United States
ViiV Healthcare
Pfizer

Completed

Multicenter, Safety Study Of Maraviroc

Acquired Immunodeficiency Syndrome | HIV Infection

Brazil
Hospital Clinic of Barcelona

Unknown

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 (DIS-MVC)

HIV-1 Infection

Spain

3

Subscribe